全球同種異體幹細胞市場規模、佔有率及成長分析（按類型、應用、最終用戶和地區）- 產業預測（2025-2032）

預計 2023 年全球同種異體幹細胞市場規模將達到 2.583 億美元，從 2024 年的 3.2494 億美元成長到 2032 年的 20.3822 億美元，預測期內（2025-2032 年）的複合年成長率為 25.8%。

全球同種異體幹細胞市場正經歷強勁成長，這得益於慢性病和退化性疾病日益普及的推動。從健康捐贈者身上採集的幹細胞為癌症、心血管疾病和自體免疫疾病等疾病提供了一種有希望的治療方案。作為一種“現成的治療方法”，幹細胞比自體治療方法具有顯著的競爭優勢，人們對可擴展且可及的細胞療法的興趣日益濃厚，這與再生醫學研究的蓬勃發展相吻合。然而，該市場面臨免疫排斥和移植物抗宿主疾病 (GvHD) 等挑戰，使患者面臨免疫力缺乏的風險。此外，複雜且昂貴的製造流程、冗長的監管障礙以及對捐贈細胞可用性的倫理擔憂，都對市場擴張構成了重大障礙。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 第二手/一級資訊來源
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

同種異體幹細胞市場規模（按類型）及複合年成長率（2025-2032）

• 市場概覽
• 間質幹細胞（MSCs）
• 造血幹細胞（HSC）
• 誘導性多功能幹細胞（iPSC）
• 胚胎幹細胞（ES細胞）

同種異體幹細胞市場規模（依應用）及複合年成長率（2025-2032）

• 市場概覽
• 腫瘤學（癌症）
• 心血管疾病
• 整形外科疾病
• 神經系統疾病
• 自體免疫疾病
• 創傷治療

異體幹細胞市場規模（依最終用戶分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院和診所
• 生物技術和製藥公司
• 學術研究機構

同種異體幹細胞市場規模，複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Mesoblast Limited（Australia）
• Athersys, Inc.（United States）
• Pluristem Therapeutics Inc.（Israel）
• Osiris Therapeutics（United States）
• Gamida Cell（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（Kite Pharma）（United States）
• Bristol Myers Squibb（Juno Therapeutics）（United States）
• Allogene Therapeutics（United States）
• Fate Therapeutics（United States）
• Century Therapeutics（United States）
• Sana Biotechnology（United States）
• Cynata Therapeutics Limited（Australia）
• Lineage Cell Therapeutics, Inc.（United States）

結論和建議

Global Allogeneic Stem Cells Market size was valued at USD 258.3 million in 2023 and is poised to grow from USD 324.94 million in 2024 to USD 2038.22 million by 2032, growing at a CAGR of 25.8% during the forecast period (2025-2032).

The global allogeneic stem cells market is witnessing robust growth, fueled by the increasing incidence of chronic and degenerative diseases. These stem cells, derived from healthy donors, present promising treatment solutions for conditions such as cancer, cardiovascular issues, and autoimmune disorders. Their ability to function as "off-the-shelf therapies" provides a significant competitive edge over autologous treatments, and rising interest in scalable, accessible cell therapies aligns with the surge in regenerative medicine initiatives. Nevertheless, the market faces challenges, including immune rejection and Graft-versus-Host disease (GvHD), which keep patients at risk of immunocompromise. Additionally, the intricate and costly manufacturing processes, along with lengthy regulatory hurdles and ethical concerns regarding donor cell availability, pose substantial barriers to market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Allogeneic Stem Cells market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Allogeneic Stem Cells Market Segments Analysis

Global Allogeneic Stem Cells Market is segmented by Type, Application, End User and region. Based on Type, the market is segmented into Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs), Induced Pluripotent Stem Cells (iPSCs) and Embryonic Stem Cells (ESCs). Based on Application, the market is segmented into Oncology (Cancer), Cardiovascular Diseases, Orthopaedic Disorders, Neurological Disorders, Autoimmune Diseases and Wound Healing. Based on End User, the market is segmented into Hospitals & Clinics, Biotechnology & Pharmaceutical Companies and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Allogeneic Stem Cells Market

The Global Allogeneic Stem Cells market is significantly driven by the advantages of sourcing stem cells from healthy donors, as opposed to autologous therapies which are reliant on individual patients. Allogeneic stem cells are produced in large quantities, leading to immediate availability for treatment. This bulk manufacturing creates a cost-efficient model that promotes widespread access to cutting-edge therapies across various applications and diseases. By offering an off-the-shelf solution, allogeneic stem cells facilitate quicker and easier implementation of innovative treatments, thereby expanding their potential impact in the healthcare market and enhancing patient care opportunities on a broader scale.

Restraints in the Global Allogeneic Stem Cells Market

A significant challenge in the allogeneic stem cell market is the risk of immune rejection by the recipient's body or the donor cells attacking the recipient's tissue, a condition known as Graft-versus-Host Disease (GVHD). This complication often necessitates the use of immunosuppressive medications, which can lead to substantial side effects and potentially diminish the effectiveness of the treatment. Consequently, the need for ongoing management of these adverse effects can hinder patient compliance and overall treatment outcomes, creating a notable restraint on the market for allogeneic stem cell therapies.

Market Trends of the Global Allogeneic Stem Cells Market

The global allogeneic stem cells market is witnessing a significant shift as researchers focus on the development of hypoimmunogenic "stealth" cells, which are designed to evade rejection by the patient's immune system. Leveraging advanced gene-editing technologies, such as CRISPR, these universal donor cells hold the promise of revolutionizing therapeutic approaches by potentially obviating the need for immunosuppressive drugs. This innovation is anticipated to enhance the safety and efficacy of stem cell therapies, thereby attracting greater investment and interest in clinical applications. Consequently, this trend is likely to propel the growth of the allogeneic stem cells market, paving the way for more accessible treatments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Allogeneic Stem Cells Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mesenchymal Stem Cells (MSCs)
• Hematopoietic Stem Cells (HSCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Embryonic Stem Cells (ESCs)

Global Allogeneic Stem Cells Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology (Cancer)
• Cardiovascular Diseases
• Orthopaedic Disorders
• Neurological Disorders
• Autoimmune Diseases
• Wound Healing

Global Allogeneic Stem Cells Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes

Global Allogeneic Stem Cells Market Size & CAGR (2025-2032)

• North America (Type, Application, End User)
  • US
  • Canada
• Europe (Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athersys, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluristem Therapeutics Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (Kite Pharma) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Juno Therapeutics) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Century Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sana Biotechnology (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations